AUCKLAND, New Zealand, Oct. 14, 2016 /PRNewswire/ -- Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today welcomed new research on the benefits of its Optiflow™ nasal high flow therapy. This research ...

Fisher & Paykel Healthcare has been a beneficiary of the coronavirus pandemic with increased demand for hospital hardware items driving two recent profit upgrades. We increase our near-term outlook ...

Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) today announced the introduction of a range of innovative new products for use with the AIRVO 2 system. These new products, used in ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

Fisher & Paykel Healthcare has lifted its full-year profit 10 per cent to a record $NZ209.02m. (AAP) Fisher & Paykel's respiratory and home care products have helped ...

Fisher & Paykel Healthcare has become the first Kiwi company to be worth $20 billion after its shares jumped again on the NZX. The milestone has been achieved on the back of a 37 per cent increase in ...